Bart Klein
Director/Board Member at The Netherlands Biotech Industry Association
Profile
Bart Klein is currently the Director at The Netherlands Biotech Industry Association.
Prior to this, he worked as the Global Head-Intellectual Property & Licensing at Royal KPN NV.
He also worked as the Executive VP-Legal & Intellectual Property at Crucell NV from 2001 to 2012.
Before that, he was a Patent Attorney at Mogen International Nv and a Senior Patent Attorney at Gist-Brocades NV.
Additionally, he served as a Member-Supervisory Board at DCPrime BV.
Bart Klein active positions
| Companies | Position | Start |
|---|---|---|
| The Netherlands Biotech Industry Association | Director/Board Member | - |
Former positions of Bart Klein
| Companies | Position | End |
|---|---|---|
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | General Counsel | 31/12/2011 |
Mogen International Nv
 Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Corporate Officer/Principal | - |
| Gist-Brocades NV | Corporate Officer/Principal | - |
| ROYAL KPN N.V. | Corporate Officer/Principal | - |
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ROYAL KPN N.V. | Communications |
| Private companies | 5 |
|---|---|
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
| The Netherlands Biotech Industry Association | |
| Gist-Brocades NV | |
Mogen International Nv
Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Health Technology |
- Stock Market
- Insiders
- Bart Klein